U.S. Medicines Marketed by Our Partners
All therapeutic information provided is intended for the U.S. audience only.
These treatments may not be available in countries outside the U.S. or may be available under a different trademark; in different strengths; or for different indications. Countries outside the U.S. may have different regulatory requirements that would call for different information to be available.
U.S. Medicines Licensed to Our Partners
We have granted licenses to medicines which enable third parties to develop, make available and, in some cases, manufacture.
Such arrangements in the U.S. include the following:
About Nektar and AstraZeneca Agreement for Movantik
Under a global agreement between Nektar and AstraZeneca, AstraZeneca is responsible for all development and commercialization. In 2016, AstraZeneca transferred the rights to sell and develop Moventig (naloxegol) in the European Union (EU), Iceland, Norway, Switzerland and Liechtenstein to Kyowa Hakko Kirin Co. Ltd. In 2020, AstraZeneca sublicensed its global rights to Movantik (excluding Europe, Canada & Israel) to RedHill Biopharma.
MOVANTIK is a registered trademark of the AstraZeneca group of companies.
Nektar Therapeutics and Baxalta Agreement for ADYNOVATE
Under a collaboration with Baxter and then Baxalta, we developed ADYNOVATE, an extended half-life recombinant factor VIII (rFVIII) treatment for Hemophilia. In January 2019, Takeda Pharmaceutical Company Limited acquired Baxalta and ADYNOVATE through its acquisition of Shire plc.
U.S. Medicines Using Our Technologies
We have granted licenses to our technologies which enable third parties to develop, provide and, in some cases, manufacture.
ADYNOVATE is a registered trademarks of Baxalta Incorporated, a Takeda company.
